Melanoma & Skin Cancer

Experts convened during an OncLive Scientific Interchange and Workshop to discuss the evolving treatment landscapes in CSCC and melanoma.

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

The prescribing information for cosibelimab in advanced cutaneous squamous cell carcinoma was updated to include long-term data from the CK-301-101 trial.

Biofrontera has submitted a sNDA to the FDA seeking the approval of aminolevulinic acid gel plus PDT in sBCC.

Cemiplimab wins EU approval after C-POST shows DFS gains for high-risk CSCC, marking the first effective adjuvant immunotherapy option.

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

AMT-253 delivered durable responses in patients with melanoma with manageable toxicity, supporting continued development.

Marlana Orloff, MD, discusses data for the combination of darovasertib and crizotinib in metastatic uveal melanoma.

Three experts spotlight key trials from the 2025 ESMO Congress investigating novel cancer vaccines across solid tumors.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in October 2025.

Belzutifan-based combinations meet end points in RCC, imaging agent under review for SSTR-positive neuroendocrine tumors, and more.

Seven provinces have agreed to reimburse cemiplimab for the treatment of patients with advanced non–small cell lung cancer and basal cell carcinoma.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

Darovasertib plus crizotinib improved OS to 21.1 months and boosted response rates in first-line metastatic uveal melanoma vs historical approaches.

EVX-01 plus pembrolizumab generated an overall response rate of 75% and durable T-cell responses in advanced melanoma.

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

Adjuvant cemiplimab significantly cut recurrence risk and improved disease-free survival in high-risk CSCC, establishing a new standard of care.

The FDA granted fast track to NBM-BMX, a HDAC8 inhibitor, for metastatic uveal melanoma.

Neoadjuvant nivolumab plus ipilimumab proved superior to adjuvant nivolumab alone with longer follow-up data from the NADINA trial in stage III melanoma.

IO102-IO103 plus pembrolizumab was associated with a clinically relevant improvement in median progression-free survival.

Will the FDA approve a resubmitted biologics license application for RP1 plus nivolumab in advanced melanoma after progression on anti–PD-1 therapy?

Pembrolizumab plus lenvatinib was safe and active in HLA-A*02:01–negative and –positive uveal melanoma.

Adjuvant nivolumab significantly extended RFS vs ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

Adjuvant cemiplimab and placebo were associated with similar rates of second primary tumors in high-risk CSCC.

BNT111 plus cemiplimab achieved an 18.1% ORR in PD-(L)1–refractory melanoma, meeting its primary end point in the phase 2 BNT111-01 trial.